Healio10d
Median hereditary angioedema attack rates fall to zero for children with berotralstat
Children with hereditary angioedema saw early and sustained reductions in monthly attack rates with berotralstat, with a ...
Nasdaq11d
Pharvaris Reports Sustained Reduction in HAE Attack Rates and Improved Quality of Life Across Long-Term Deucrictibant Studies
The reduced monthly HAE attack rate was maintained for at least 1.5 years in the CHAPTER-1 OLE study. What improvements did participants report in the CHAPTER-1 OLE study? All participants ...
Business Insider11d
Pharvaris Presents Long-Term Clinical Data of Deucrictibant for the Prevention and Treatment of HAE Attacks at the 2025 AAAAI/WAO Joint Congress
Reduced monthly HAE attack rate maintained for at least 1.5 years in CHAPTER-1 OLE study; median proportion of days with symptoms in OLE was further reduced to zero days All participants in ...
Astria Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the ...
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update
KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today released financial results for the third fiscal quarter ended January 31 ...
Physician's Weekly3d
Bradykinin Detection Aids Diagnosis In Recurrent Angioedema
The following is a summary of “Novel Bradykinin Detection In The Diagnostic Workup Of Patients With Recurrent Angioedema ...
Business Wire11d
KalVista Pharmaceuticals Shares Latest Sebetralstat Findings at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting
“The growing body of data from the KONFIDENT-S study consistently demonstrate that sebetralstat enabled early treatment and fast symptom relief from HAE attacks, regardless of age, attack ...